A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.

被引：0
|
作者：
Ali, Haris
Kishtagari, Ashwin
Maher, Keri Renee
Mohan, Sanjay
Mazumder, Amitabha
Chamoun, Kamal
Karasik, Igor
Sbar, Eric
Dugon, Laura
Tamir, Sharon
Wang, Xulong
Prchal, Josef T.
Tantravahi, Srinivas Kiran
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Mt Sinai St Lukes Roosevelt Hosp, New York, NY USA
[3] VCU Massey Canc Ctr, Richmond, VA USA
[4] Vanderbilt Univ Sch Med, Nashville, TN USA
[5] Oncol Inst Hope Innovat, Tampa, FL USA
[6] Karyopharm Therapeutics Inc, Newton, MA USA
[7] Karyopharm Therapeut, Newton, MA USA
[8] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[9] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7060
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Open-label, phase I/II dose-escalation study of ARANESP™ in patients with chronic anemia of cancer.
    Glaspy, J
    Meza, L
    Smith, R
    Fleishman, A
    Mendes, E
    Colowick, A
    BLOOD, 2000, 96 (11) : 154B - 155B
  • [22] A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage
    Pemmaraju, Naveen
    Gundabolu, Krishna
    Snyder, Jack
    Silverman, Michael H.
    Bardelli, Geraldine
    Verstovsek, Srdan
    Schiller, Gary J.
    BLOOD, 2022, 140 : 6821 - 6822
  • [23] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Andrea Wang-Gillam
    William Schelman
    Stacey Ukrainskyj
    Caly Chien
    Martha Gonzalez
    Zhao Yang
    Marek Kania
    Heather Yeckes-Rodin
    Investigational New Drugs, 2023, 41 (6) : 851 - 860
  • [24] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [25] Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
    Chen, Qiuyan
    Tang, Linquan
    Liu, Na
    Han, Feng
    Guo, Ling
    Guo, Shanshan
    Wang, Jianwei
    Liu, Huai
    Ye, Yanfang
    Zhang, Lu
    Liu, Liting
    Wang, Pan
    Li, Yingqin
    He, Qingmei
    Yang, Xiaoqun
    Tang, Qingnan
    Li, Yang
    Liang, YuJing
    Sun, XueSong
    Xie, Chuanmiao
    Mo, Yunxian
    Guo, Ying
    Sun, Rui
    Mo, Haoyuan
    Cao, Kajia
    Guo, Xiang
    Zeng, Musheng
    Mai, Haiqiang
    Ma, Jun
    CANCER COMMUNICATIONS, 2018, 38
  • [26] OPEN-LABEL, DOSE-ESCALATION, PHASE 1 STUDY OF SAFETY AND PHARMACOKINETICS OF DICHLOR-PHENAMIDE IN HEALTHY VOLUNTEERS
    Cohen, F.
    MUSCLE & NERVE, 2017, 56 : S10 - S10
  • [27] Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
    Wang-Gillam, Andrea
    Schelman, William
    Ukrainskyj, Stacey
    Chien, Caly
    Gonzalez, Martha
    Yang, Zhao
    Kania, Marek
    Yeckes-Rodin, Heather
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (06) : 851 - 860
  • [28] A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia
    Zwaan, C. Michel
    Soderhall, Stefan
    Brethon, Benoit
    Luciani, Matteo
    Rizzari, Carmelo
    Stam, Ronald W.
    Besse, Emmanuelle
    Dutreix, Catherine
    Fagioli, Franca
    Ho, Phoenix A.
    Dufour, Carlo
    Pieters, Rob
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 623 - 627
  • [29] Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
    Harrison, Claire N.
    Gupta, Vikas K.
    Gerds, Aaron T.
    Rampal, Raajit
    Verstovsek, Srdan
    Talpaz, Moshe
    Kiladjian, Jean-Jacques
    Mesa, Ruben
    Kuykendall, Andrew T.
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Grosicki, Sebastian
    Devos, Timothy
    Jourdan, Eric
    Wondergem, Marielle J.
    Al-Ali, Haifa Kathrin
    Buxhofer-Ausch, Veronika
    Alvarez-Larran, Alberto
    Patriarca, Andrea
    Kremyanskaya, Marina
    Mead, Adam J.
    Akhani, Sanjay
    Sheikine, Yuri
    Colak, Gozde
    Mascarenhas, John
    FUTURE ONCOLOGY, 2022, 18 (27) : 2987 - 2997
  • [30] A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers.
    Gutierrez, Martin
    Giaccone, Giuseppe
    Harper, Harry D.
    Liu, Stephen V.
    Fang, Bruno
    Ruiz, Jimmy
    Hinson, James M.
    Orlemans, Everardus Otto
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345